[1] G. M. Brodeur and J. M. Maris, “Neuroblastoma,” In: P. A. Pizzo and D. G. Poplack, Eds., Principles and Practice of Pediatric Oncology, Lippincott Williams & Wilkins, Philadelphia, 2006, pp. 933-970.
[2] K. Oberg, “Advances in Chemotherapy and Biotherapy of Endocrine Tumors,” Current Opinion in Oncology, Vol. 10, No. 1, 1998, pp. 58-65. doi:10.1097/00001622-199801000-00010
[3] W. J. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster and B. Brans, “Targeted Therapy in Nuclear Medicine—Current Status and Future Prospects,” Annals of Oncology, Vol. 18, No. 11, 2007, pp. 1782-1792. doi:10.1093/annonc/mdm111
[4] M. Miano, A. Garaventa, et al., “Megatherapy Combining I(131) Metaiodobenzylguanidine and High-Dose Chemotherapy with Haematopoietic Progenitor Cell Rescue for Neuroblastoma,” Bone Marrow Transplant, Vol. 27, 2001, pp. 571-574.
[5] J. De Kraker, C. A. Hoefnagel, H. Caron, et al., “First Line Targeted Radiotherapy, a New Concept in the Treatment of Advanced Stage Neuroblastoma,” European Journal of Cancer, Vol. 31, No. 4, 1995, pp. 600-602. doi:10.1016/0959-8049(95)00063-O
[6] S. S. Goldberg, K. DeSantes, J. P. Huberty, et al., “Engraftment after Myeloablative Doses of 131I-Metaiodobenzylguanidine Followed by Autologous Bone Marrow Transplantation for Treatment of Refractory Neuroblastoma,” Medical and Pediatric Oncology, Vol. 30, No. 6, 1998, pp. 339-346. doi:10.1002/(SICI)1096-911X(199806)30:6<339::AID-MPO7>3.0.CO;2-F
[7] C. A. Hoefnagel, P. A. Voute, J. de Kraker and H. R. Marcuse, “Radionuclide Diagnosis and Therapy of Neural Crest Tumors Using Iodine-131 Metaiodobenzylguanidine,” Journal of Nuclear Medicine, Vol. 28, 1987, pp. 308-314.
[8] C. A. Hoefnagel, J. De Kraker, R. A. Valdes Olmos and P. A. Voute, “131I-MIBG as a First-Line Treatment in High-Risk Neuroblastoma Patients,” Nuclear Medicine Communications, Vol. 15, No. 9, 1994, pp. 712-717. doi:10.1097/00006231-199409000-00008
[9] S. Meller, “Targeted Radiotherapy for Neuroblastoma,” Archives of Disease in Childhood, Vol. 77, 1997, pp. 389-391. doi:10.1136/adc.77.5.389
[10] G. M. Brodeur, J. Pritchard, F. Berthold, et al., “Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment,” Journal of Clinical Oncology, Vol. 11, 1993, pp. 1466-1477.
[11] A. Garaventa, B. De Bernardi, C. Pianca, et al., “Localized but Unresectable Neuroblastoma: Treatment and Outcome of 145 Cases,” Journal of Clinical Oncology, Vol. 9, 1993, pp. 1770-1779.
[12] G. M. Haase, J. B. Atkinson, D. O. Stram, J. N. Lukens and K. K. Matthay, “Surgical Management and Outcome of Locoregional Neuroblastoma: Comparison of the Children Cancer Group and the International Staging System,” Journal of Pediatric Surgery, Vol. 30, No. 2, 1995, pp. 289-295. doi:10.1016/0022-3468(95)90576-6
[13] T. Philip, R. Ladenstein, C. Lasset, et al., “1070 Myeloablative Megatherapy Procedures Followed by Stem Cell Rescue for Neuroblastoma: 17 Years of European Experience and Conclusions,” European Journal of Cancer, Vol. 33, No. 12, 1997, pp. 2130-2135. doi:10.1016/S0959-8049(97)00324-9
[14] W. Weber, J. Weber and R. Senekowitsch-Schmidtke, “Therapeutic Effect of M-[I-131]- and M-[I-125] Iodobenzylguanidine on Neuroblastoma Multicellular Tumor Spheroids of Different Sizes,” Cancer Research, Vol. 56, 1996, pp. 5428-5434.
[15] D. Schwabe, St. Sahm, V. Gerein, et al., “131-Metaiodobenzylguanidine Therapy of Neuroblastoma in Childhood,” European Journal of Pediatrics, Vol. 146, No. 3, 1987, pp. 246-250. doi:10.1007/BF00716467
[16] T. Klingebiel, J. Treuner, G. Ehninger, et al., “[I-131]-Metaiodobenzylguanidine in the Treatment of Metastatic Neuroblastoma,” Cancer Chemotherapy and Pharmacology, Vol. 25, No. 2, 1989, pp. 143-148. doi:10.1007/BF00692356
[17] L. S. Lashford, I. J. Lewis, S. L. Fielding, et al., “Phase I/II Study of Iodine 131 Metaiodobenzylguanidine in Chemoresistant Neuroblastoma: A United Kingdom Children Cancer Study Group Investigation,” Journal of Clinical Oncology, Vol. 10, 1992, pp. 1889-1896.
[18] E. J. Van Hasselt, H. A. Heij, J. De Kraker, A. Vos and P. A. Voute, “Pretreatment with [I-131]Metaiodobenzylguanidine and Surgical Resection of Advanced Neuroblastom,” European Journal of Pediatric Surgery, Vol. 6, No. 3, 1996, pp. 155-159. doi:10.1055/s-2008-1066495
[19] R. Mastrangelo, A. Tornesello and S. Mastrangelo, “Role of 131 Metaiodobenzylguanidine in the Treatment of Neuroblastoma,” Medical and Pediatric Oncology, Vol. 31, No. 1, 1998, pp. 22-26. doi:10.1002/(SICI)1096-911X(199807)31:1<22::AID-MPO5>3.0.CO;2-1
[20] A. Garaventa, O. Bellagamba, M. S. Lo Piccolo, et al., “I-131 Metaiodobenzylguanidine (I-131MIBG) Therapy for Residual Neuroblastoma: A Mono-Institutional Experience with 43 Patients,” British Journal of Cancer, Vol. 81, No. 8, 1999, pp. 1378-1884.